Branko J Drakulić

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4105622/publications.pdf

Version: 2024-02-01

29 294 11 17
papers citations h-index g-index

29 29 29 485
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Role of complexes formation between drugs and penetration enhancers in transdermal delivery. International Journal of Pharmaceutics, 2008, 363, 40-49.	5.2	29
2	(E)-4-Aryl-4-oxo-2-butenoic acid amides, chalcone–aroylacrylic acid chimeras: Design, antiproliferative activity and inhibition of tubulin polymerization. European Journal of Medicinal Chemistry, 2013, 62, 40-50.	5.5	29
3	4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure–activity relationship based on molecular interaction fields. Bioorganic and Medicinal Chemistry, 2010, 18, 1181-1193.	3.0	24
4	Isothermal kinetics of (E)-4-(4-metoxyphenyl)-4-oxo-2-butenoic acid release from poly(acrylic acid) hydrogel. Thermochimica Acta, 2007, 466, 38-48.	2.7	20
5	Structural modifications of 4-aryl-4-oxo-2-aminylbutanamides and their acetyl- and butyrylcholinesterase inhibitory activity. Investigation of AChE–ligand interactions by docking calculations and molecular dynamics simulations. European Journal of Medicinal Chemistry, 2014, 81, 158-175.	5.5	20
6	Antiproliferative activity of aroylacrylic acids. Structure-activity study based on molecular interaction fields. European Journal of Medicinal Chemistry, 2011, 46, 3265-3273.	5 . 5	19
7	An alignment independent 3D QSAR study of the antiproliferative activity of 1,2,4,5-tetraoxanes. European Journal of Medicinal Chemistry, 2010, 45, 4570-4577.	5.5	18
8	The 3D-QSAR study of 110 diverse, dual binding, acetylcholinesterase inhibitors based on alignment independent descriptors (GRIND-2). The effects of conformation on predictive power and interpretability of the models. Journal of Molecular Graphics and Modelling, 2012, 38, 194-210.	2.4	18
9	5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII. Bioorganic and Medicinal Chemistry, 2015, 23, 4649-4659.	3.0	18
10	An LFER study of the protolytic equilibria of 4-aryl-2,4-dioxobutanoic acids in aqueous solutions. Journal of the Serbian Chemical Society, 2007, 72, 1201-1216.	0.8	16
11	Aryldiketo Acids Have Antibacterial Activity Against MDR <i>Staphylococcus aureus</i> Strains: Structural Insights Based on Similarity and Molecular Interaction Fields. ChemMedChem, 2009, 4, 1971-1975.	3.2	13
12	2-[(Carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic Acids Selectively Suppressed Proliferation of Neoplastic Human HeLa Cells. A SAR/QSAR Study. Journal of Medicinal Chemistry, 2005, 48, 5600-5603.	6.4	11
13	A QSAR study of acute toxicity of N-substituted fluoroacetamides to rats. Chemosphere, 2006, 62, 641-649.	8.2	11
14	Conformational mobility of active and E-64-inhibited actinidin. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4790-4799.	2.4	9
15	Antiproliferative Activity of \hat{l}^2 -Hydroxy- \hat{l}^2 -Arylalkanoic Acids. International Journal of Molecular Sciences, 2007, 8, 214-228.	4.1	7
16	Solvatochromism of symmetrical 2,6-distyrylpyridines. An experimental and theoretical study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2015, 135, 435-446.	3.9	6
17	Linear free energy relationships of half-wave reduction potentials of (E)-4-aryl-4-oxo-2-butenoic acids. Tetrahedron Letters, 2010, 51, 734-738.	1.4	4
18	Antiproliferative activity of NCI-DTP glutarimide derivatives. An alignment independent 3D QSAR study. Journal of the Serbian Chemical Society, 2010, 75, 1167-1179.	0.8	4

#	Article	IF	CITATIONS
19	Reactivity of (E)-4-aryl-4-oxo-2-butenoic acid phenylamides with piperidine and benzylamine: kinetic and theoretical study. Monatshefte Fýr Chemie, 2014, 145, 1297-1306.	1.8	4
20	The Effect of Phenyl Substituents on 13C NMR Shifts and Metal Ions Binding to 4-Phenyl-2,4-Dioxobutanoic Acid Derivatives. Letters in Organic Chemistry, 2008, 5, 692-699.	0.5	3
21	Spectroscopic properties and antimicrobial activity of dioxomolybdenum(VI) complexes with heterocyclic S,S'-ligands. Journal of the Serbian Chemical Society, 2012, 77, 53-66.	0.8	3
22	Antiproliferative activity of the Michael adducts of aroylacrylic acids and cyclic amines. Molecular Diversity, 2014, 18, 577-592.	3.9	3
23	Synthesis, structure and magnetic properties of the first copper(II) complex with an (E)-4-aryl-4-oxo-2-butenoato ligand. Inorganic Chemistry Communication, 2006, 9, 1173-1177.	3.9	2
24	Reactivity of (E)-4-aryl-4-oxo-2-butenoic acid arylamides toward 2-mercaptoethanol. A LFER study. Monatshefte FÁ½r Chemie, 2013, 144, 1815-1824.	1.8	2
25	Acute Toxicity of Substituted 2â€(<i>1H</i> à€pyrazolâ€1â€yl)acetanilides and Related Commercially Available Local Anesthetics Toward Mice. A GRIND/ALMONDâ€Based 3â€D QSAR Study. QSAR and Combinatorial Science, 2009, 28, 206-217.	1.4	1
26	2-[(Carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic Acids Suppressed Survival of Neoplastic Human HeLa Cells: A QSAR Study. Phosphorus, Sulfur and Silicon and the Related Elements, 2005, 180, 1487-1488.	1.6	0
27	Weak intermolecular interactions in 11-chloro-2,3,4,5-tetrahydro-1H-cyclohepta[b]quinoline. Acta Crystallographica Section C: Crystal Structure Communications, 2008, 64, o502-o504.	0.4	0
28	On the choice of optimal conformation in linear free-energy relationships. Reactivity of 2-[(carboxymethyl)sulfanyl]-4-oxo-4-arylbutanoic acids with diphenyldiazomethane. Tetrahedron Letters, 2012, 53, 553-556.	1.4	0
29	Dynamics of Uninhibited and Covalently Inhibited Cysteine Protease on Non-physiological pH. Modeling and Optimization in Science and Technologies, 2014, , 75-82.	0.7	0